Last Price
9.90
Today's Change
+0.33 (3.44%)
Day's Change
9.70 - 12.00
Trading Volume
4,031,910
Exchange: NASDAQ Global Select NASDAQ Global Select
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Mr. Thomas Andrew Butler Mr. Thomas Andrew Butler
Full Time Employees: 112 112
IPO Date: 2021-04-16 2021-04-16
CIK: 0001840439 0001840439
ISIN: US09077A1060 US09077A1060
CUSIP: 09077A106 09077A106
Beta: -0.49 -0.49
Last Dividend: 0.00 0.00
Dcf Diff: 5.10 5.10
Dcf: 4.88 4.88
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.